Download PDF
Semin Thromb Hemost 2017; 43(05): 505-513
DOI: 10.1055/s-0036-1597285
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Risk Stratification Models in Atrial Fibrillation

Farhan Shahid
1   University of Birmingham, Institute of Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom
,
Gregory Y. H. Lip
1   University of Birmingham, Institute of Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom
2   Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark
› Author Affiliations
Further Information

Publication History

Publication Date:
27 January 2017 (online)

    Permissions and Reprints

Abstract

Atrial fibrillation (AF) is associated with an increased risk of stroke compared with the general population. AF-related stroke confers a higher mortality and morbidity risk, and thus, early detection and assessment for the initiation of effective stroke prevention with oral anticoagulation are crucial. Simple and practical risk assessment tools are essential to facilitate stroke and bleeding risk assessment in busy clinics and wards to aid decision making. At present, the CHA2DS2VASc score is recommended by guidelines as the most simple and practical method of assessing stroke risk in AF patients. Alongside this, the use of the HAS-BLED score aims to identify patients at high risk of bleeding for more regular review and follow-up, and draws attention to potentially reversible bleeding risk factors. The aim of this review article is to summarize the current risk scores available for both stroke and bleeding in AF patients, and the recommendations for their use.

Keywords

atrial fibrillation - stroke - risk scores - bleeding - CHA2DS2VASc - HAS-BLED - anticoagulation
 

  • References

  • 1 Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J 2012; 76 (10) 2289-2304
    CrossrefPubMedGoogle Scholar
  • 2 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
    CrossrefPubMedGoogle Scholar
  • 3 Camm AJ, Lip GY, De Caterina R. , et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33 (21) 2719-2747
    CrossrefPubMedGoogle Scholar
  • 4 National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation. (Clinical guidelines 180). Available at nice.org.uk
    PubMedGoogle Scholar
  • 5 Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69 (06) 546-554
    CrossrefPubMedGoogle Scholar
  • 6 Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. Eur Heart J 2013; 34 (14) 1041-1049
    CrossrefPubMedGoogle Scholar
  • 7 Banerjee A, Fauchier L, Bernard-Brunet A, Clementy N, Lip GY. Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project. Thromb Haemost 2014; 111 (03) 549-556
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Lip GY, Skjøth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015; 114 (04) 826-834
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Fauchier L, Clementy N, Bisson A. , et al. Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?. Stroke 2016; 47 (07) 1831-1836
    CrossrefPubMedGoogle Scholar
  • 10 Stöllberger C, Chnupa P, Abzieher C. , et al. Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. Clin Cardiol 2004; 27 (01) 40-46
    CrossrefPubMedGoogle Scholar
  • 11 Cabin HS, Clubb KS, Hall C, Perlmutter RA, Feinstein AR. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol 1990; 65 (16) 1112-1116
    CrossrefPubMedGoogle Scholar
  • 12 van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A. ; European Atrial Fibrillation Trial (EAFT) Study Group. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. Stroke 1995; 26 (05) 801-806
    CrossrefPubMedGoogle Scholar
  • 13 Lauw MN, Vanassche T, Masiero S, Eikelboom JW, Connolly SJ. Abstract 20413: pattern of atrial fibrillation and the risk of ischemic stroke - a systematic review and meta-analysis. Circulation 2014; 130 (Suppl. 02) A20413
    PubMedGoogle Scholar
  • 14 Vanassche T, Lauw MN, Eikelboom JW. , et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015; 36 (05) 281-7a
    CrossrefPubMedGoogle Scholar
  • 15 Steinberg BA, Hellkamp AS, Lokhnygina Y. , et al; ROCKET-AF Steering Committee and Investigators. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 2015; 36 (05) 288-296
    CrossrefPubMedGoogle Scholar
  • 16 Hughes M, Lip GY. ; Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99 (02) 295-304
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. ; The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 1999; 30 (06) 1223-1229
    CrossrefPubMedGoogle Scholar
  • 18 Wang TJ, Massaro JM, Levy D. , et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290 (08) 1049-1056
    CrossrefPubMedGoogle Scholar
  • 19 Inoue H, Atarashi H. ; Research Group for Antiarrhythmic Drug Therapy. Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. Am J Cardiol 2000; 86 (08) 852-855
    CrossrefPubMedGoogle Scholar
  • 20 Miyasaka Y, Barnes ME, Gersh BJ. , et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114 (02) 119-125
    CrossrefPubMedGoogle Scholar
  • 21 Chao TF, Wang KL, Liu CJ. , et al. Age threshold for increased stroke risk among patients with atrial fibrillation: a Nationwide Cohort Study from Taiwan. J Am Coll Cardiol 2015; 66 (12) 1339-1347
    CrossrefPubMedGoogle Scholar
  • 22 Cove CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM. Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms. Thromb Haemost 2014; 111 (03) 385-391
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. QJM 2014; 107 (12) 955-967
    CrossrefPubMedGoogle Scholar
  • 24 Overvad TF, Rasmussen LH, Skjøth F. , et al. Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. The prospective Danish Diet, Cancer and Health study. Thromb Haemost 2014; 112 (04) 789-795
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ 2012; 344: e3522
    CrossrefPubMedGoogle Scholar
  • 26 Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 2012; 10 (09) 1745-1751
    CrossrefPubMedGoogle Scholar
  • 27 Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Hormone replacement therapy and adverse outcomes in women with atrial fibrillation: an analysis from the atrial fibrillation follow-up investigation of rhythm management trial. Stroke 2014; 45 (10) 3076-3079
    CrossrefPubMedGoogle Scholar
  • 28 Anandasundaram B, Lane DA, Apostolakis S, Lip GY. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. J Thromb Haemost 2013; 11 (05) 975-987
    CrossrefPubMedGoogle Scholar
  • 29 Pedersen OD, Bagger H, Køber L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999; 20 (10) 748-754
    CrossrefPubMedGoogle Scholar
  • 30 Siu CW, Jim MH, Ho HH. , et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. Chest 2007; 132 (01) 44-49
    CrossrefPubMedGoogle Scholar
  • 31 Rasmussen LH, Larsen TB, Due KM, Tjønneland A, Overvad K, Lip GY. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study. J Thromb Haemost 2011; 9 (07) 1301-1307
    CrossrefPubMedGoogle Scholar
  • 32 Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33 (12) 1500-1510
    CrossrefPubMedGoogle Scholar
  • 33 Olesen JB, Lip GY, Lane DA. , et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med 2012; 125 (08) 826.e13-826.e23
    PubMedGoogle Scholar
  • 34 Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103 (04) 683-685
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285 (22) 2864-2870
    CrossrefPubMedGoogle Scholar
  • 36 You JJ, Singer DE, Howard PA. , et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e531S-575S
    CrossrefPubMedGoogle Scholar
  • 37 Fuster V, Rydén LE, Cannom DS. , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114 (07) e257-e354
    CrossrefPubMedGoogle Scholar
  • 38 Lip GY, Skjøth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015; 65 (14) 1385-1394
    CrossrefPubMedGoogle Scholar
  • 39 Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107 (06) 1172-1179
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol 2012; 5 (02) 319-326
    CrossrefPubMedGoogle Scholar
  • 41 Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?. Thromb Haemost 2015; 113 (06) 1165-1169
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Lip GYH. Stroke prevention in atrial fibrillation: changing concepts. Eur Heart J Cardiovasc Pharmacother 2015; 1 (02) 76-79
    CrossrefPubMedGoogle Scholar
  • 43 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137 (02) 263-272
    CrossrefPubMedGoogle Scholar
  • 44 Xiong Q, Chen S, Senoo K, Proietti M, Hong K, Lip GY. The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients with atrial fibrillation: a systemic review and meta-analysis. Int J Cardiol 2015; 195: 237-242
    CrossrefPubMedGoogle Scholar
  • 45 Davis G, Johns EJ. Somatosensory regulation of renal function in the stroke-prone spontaneously hypertensive rat. J Physiol 1994; 481 (Pt 3): 753-759
    CrossrefPubMedGoogle Scholar
  • 46 Mostofsky E, Wellenius GA, Noheria A. , et al. Renal function predicts survival in patients with acute ischemic stroke. Cerebrovasc Dis 2009; 28 (01) 88-94
    CrossrefPubMedGoogle Scholar
  • 47 Guo Y, Wang H, Zhao X. , et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol 2013; 168 (05) 4678-4684
    CrossrefPubMedGoogle Scholar
  • 48 Piccini JP, Stevens SR, Chang Y. , et al; ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013; 127 (02) 224-232
    CrossrefPubMedGoogle Scholar
  • 49 Friberg L, Benson L, Lip GYH. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36 (05) 297-306
    CrossrefPubMedGoogle Scholar
  • 50 Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013; 346: f2573
    CrossrefPubMedGoogle Scholar
  • 51 Singer DE, Chang Y, Borowsky LH. , et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013; 2 (03) e000250
    CrossrefPubMedGoogle Scholar
  • 52 Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131 (12) 927-934
    PubMedGoogle Scholar
  • 53 Aspberg S, Chang Y, Atterman A, Bottai M, Go AS, Singer DE. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J 2016; 37 (42) 3203-3210
    CrossrefPubMedGoogle Scholar
  • 54 Nielson PB, Larsen TB, Skjoth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study. Sci Rep 2016; 6: 27410
    CrossrefPubMedGoogle Scholar
  • 55 Geller BJ, Giugliano RP, Braunwald E. , et al. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Am Heart J 2015; 170 (04) 669-674
    CrossrefPubMedGoogle Scholar
  • 56 Chao T-F, Liu C-J, Wang K-L. , et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in ‘low-risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol 2014; 64 (16) 1658-1665
    CrossrefPubMedGoogle Scholar
  • 57 Lip GY, Nielsen PB, Skjøth F, Lane DA, Rasmussen LH, Larsen TB. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. Chest 2014; 146 (05) 1337-1346
    CrossrefPubMedGoogle Scholar
  • 58 Lip GY, Andreotti F, Fauchier L. , et al; European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106 (06) 997-1011
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Camm AJ, Kirchhof P, Lip GY. , et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12 (10) 1360-1420
    CrossrefPubMedGoogle Scholar
  • 60 Gage BF, Yan Y, Milligan PE. , et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151 (03) 713-719
    CrossrefPubMedGoogle Scholar
  • 61 Fang MC, Go AS, Chang Y. , et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol 2011; 58 (04) 395-401
    CrossrefPubMedGoogle Scholar
  • 62 Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 2016; 14: 1711-1714
    CrossrefPubMedGoogle Scholar
  • 63 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
    CrossrefPubMedGoogle Scholar
  • 64 Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57 (02) 173-180
    CrossrefPubMedGoogle Scholar
  • 65 Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2013; 61 (03) 386-387
    CrossrefPubMedGoogle Scholar
  • 66 Kooiman J, van Hagen N, Iglesias Del Sol A. , et al. The HAS-BLED score identifies patients with acute venous thromboembolism at high risk of major bleeding complications during the first six months of anticoagulant treatment. PLoS One 2015; 10 (04) e0122520
    CrossrefPubMedGoogle Scholar
  • 67 Omran H, Bauersachs R, Rübenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108 (01) 65-73
    Article in Thieme ConnectPubMedGoogle Scholar
  • 68 Smith JG, Wieloch M, Koul S. , et al. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention 2012; 8 (06) 672-678
    CrossrefPubMedGoogle Scholar
  • 69 Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2015; 38 (09) 555-561
    CrossrefPubMedGoogle Scholar
  • 70 Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol 2014; 40 (03) 277-284
    CrossrefPubMedGoogle Scholar
  • 71 Gallego P, Roldan V, Marín F. , et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110 (06) 1189-1198
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Proietti M, Senoo K, Lane DA, Lip GYH. Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores. Sci Rep 2016; 6: 24376
    CrossrefPubMedGoogle Scholar
  • 73 O'Brien EC, Simon DN, Thomas LE. , et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36 (46) 3258-3264
    PubMedGoogle Scholar
  • 74 Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin. Am J Med 2016; 129 (06) 600-607
    CrossrefPubMedGoogle Scholar
  • 75 Steinberg JS, Sadaniantz A, Kron J. , et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109 (16) 1973-1980
    CrossrefPubMedGoogle Scholar
  • 76 Lip GYH, Lane DA, Buller H, Apostolakis S. Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS study. Chest 2013; 144 (06) 1839-1847
    CrossrefPubMedGoogle Scholar